Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Alfuzosin HCl

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 996Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 81403-68-1, Alfuzosin hcl, Uroxatral, Urion, Xatral, Alfoten
    Molecular Formula
    C19H28ClN5O4
    Molecular Weight
    425.9  g/mol
    InChI Key
    YTNKWDJILNVLGX-UHFFFAOYSA-N
    FDA UNII
    75046A1XTN
    Alfuzosin Hydrochloride is the hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. Alfuzosin selectively binds to and antagonizes post-synaptic alpha-1-adrenoreceptors in smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). This agent also blocks alpha-1-adrenoreceptors in peripheral vascular smooth muscle, resulting in vasodilatation and a decrease in peripheral vascular resistance.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
    2.1.2 InChI
    InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
    2.1.3 InChI Key
    YTNKWDJILNVLGX-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    75046A1XTN
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Alfetim

    2. Alfusozine

    3. Alfuzosin

    4. Alphuzosine

    5. Benestan

    6. N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide

    7. Urion

    8. Uroxatral

    9. Xatral

    2.3.2 Depositor-Supplied Synonyms

    1. 81403-68-1

    2. Alfuzosin Hcl

    3. Uroxatral

    4. Urion

    5. Xatral

    6. Alfoten

    7. Alfuzosin (hydrochloride)

    8. Sl 77 499-10

    9. Sl 77499-10

    10. Alfuzosinhydrochloride

    11. Sl-77499-10

    12. 75046a1xtn

    13. Alfuzosin Hydrochloride (uroxatral)

    14. Alfetim

    15. Sl-77-499-10

    16. Dsstox_cid_25514

    17. Dsstox_rid_80924

    18. Dsstox_gsid_45514

    19. N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide Hydrochloride

    20. N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride

    21. Sl-7749910

    22. 81403-68-1 (alfuzosin Hcl), 81403-80-7(alfuzosin).

    23. Alfuzosin Hydrochloride [usan]

    24. Xatral Retard

    25. Xatral Od

    26. Xatral Sr

    27. Xatral Xl

    28. Chebi:32286

    29. Uroxatral (tn)

    30. N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, Monohydrochloride

    31. Unii-75046a1xtn

    32. N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)

    33. Sr-01000759345

    34. Alfuzosin Hydrochloride (jan/usan)

    35. Alfuzosin Hydrochloride [usan:usp]

    36. Mfcd00879135

    37. Sl-77499

    38. Alfuzosin Hydrochloride;

    39. Ncgc00016946-01

    40. Sl77.0499-10

    41. Cas-81403-68-1

    42. Sl-77.0499-10

    43. Alfuzosin Hydrochloride,(s)

    44. Chembl1723

    45. Alfuzosin-[d3] Hydrochloride

    46. Schembl179910

    47. Dtxsid3045514

    48. Alfuzosin For Peak Identification

    49. Hy-b0192a

    50. Alfuzosin For System Suitability A

    51. Bcpp000417

    52. Hms1569a05

    53. Alfuzosin Hydrochloride [mi]

    54. Tox21_110701

    55. Tox21_500224

    56. Alfuzosin Hydrochloride [jan]

    57. S1409

    58. (methyl)amino)propyl)tetrahydrofuran-2

    59. Akos015966770

    60. Tox21_110701_1

    61. Ac-1116

    62. Alfuzosin Hydrochloride [mart.]

    63. Bcp9000271

    64. Ccg-213373

    65. Lp00224

    66. Alfuzosin Hydrochloride [usp-rs]

    67. Alfuzosin Hydrochloride [who-dd]

    68. Ncgc00095152-09

    69. Ncgc00260909-01

    70. 2-furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, Monohydrochloride (+-)-

    71. As-14240

    72. Alfuzosin Hydrochloride [orange Book]

    73. Ft-0630890

    74. Sw196913-4

    75. Alfuzosin Hydrochloride [ep Monograph]

    76. Alfuzosin Hydrochloride [usp Monograph]

    77. D01692

    78. T71347

    79. Alfuzosin Hydrochloride, >=98% (hplc), Solid

    80. 403a681

    81. A840121

    82. Sr-01000759345-5

    83. Q27114856

    84. Alfuzosin Hydrochloride, European Pharmacopoeia (ep) Reference Standard

    85. Alfuzosin Hydrochloride, United States Pharmacopeia (usp) Reference Standard

    86. Alfuzosin For Peak Identification, European Pharmacopoeia (ep) Reference Standard

    87. Alfuzosin For System Suitability A, European Pharmacopoeia (ep) Reference Standard

    88. Alfuzosin For System Suitability, European Pharmacopoeia (ep) Reference Standard

    89. Alfuzosin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

    90. (+/-)-n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide Monohydrochloride

    91. 2-furancarboxamide, (+/-)-n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, Monohydrochloride

    92. 4-amino-6,7-dimethoxy-2-[methyl[3-[(tetrahydro-2-furoyl)amino]propyl]amino]quinazoline Hydrochloride

    93. N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)-propyl)tetrahydrofuran-2-carboxamide Hydrochloride

    94. N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl]tetrahydro-2-furancarboxamide Hydrochloride

    95. N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide Hydrochloride

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 425.9 g/mol
    Molecular Formula C19H28ClN5O4
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count8
    Exact Mass425.1829821 g/mol
    Monoisotopic Mass425.1829821 g/mol
    Topological Polar Surface Area112 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity511
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameAlfuzosin hydrochloride
    Drug LabelEach alfuzosin hydrochloride extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white powder that melts at 231 to 233C. It is freely soluble in water, sparingly solub...
    Active IngredientAlfuzosin hydrochloride
    Dosage FormTablet, extended release
    RouteOral
    Strength10mg
    Market StatusPrescription
    CompanyWockhardt; Teva Pharms; Apotex; Aurobindo Pharma; Torrent Pharms; Invagen Pharms; Sun Pharma Global; Mylan

    2 of 4  
    Drug NameUroxatral
    PubMed HealthAlfuzosin (By mouth)
    Drug ClassesBenign Prostatic Hypertrophy Agent
    Drug LabelEach UROXATRAL extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white crystalline powder that melts at approximately 240C. It is freely soluble in water, sparingly so...
    Active IngredientAlfuzosin hydrochloride
    Dosage FormTablet, extended release
    RouteOral
    Strength10mg
    Market StatusPrescription
    CompanyCovis Pharma Sarl

    3 of 4  
    Drug NameAlfuzosin hydrochloride
    Drug LabelEach alfuzosin hydrochloride extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white powder that melts at 231 to 233C. It is freely soluble in water, sparingly solub...
    Active IngredientAlfuzosin hydrochloride
    Dosage FormTablet, extended release
    RouteOral
    Strength10mg
    Market StatusPrescription
    CompanyWockhardt; Teva Pharms; Apotex; Aurobindo Pharma; Torrent Pharms; Invagen Pharms; Sun Pharma Global; Mylan

    4 of 4  
    Drug NameUroxatral
    PubMed HealthAlfuzosin (By mouth)
    Drug ClassesBenign Prostatic Hypertrophy Agent
    Drug LabelEach UROXATRAL extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white crystalline powder that melts at approximately 240C. It is freely soluble in water, sparingly so...
    Active IngredientAlfuzosin hydrochloride
    Dosage FormTablet, extended release
    RouteOral
    Strength10mg
    Market StatusPrescription
    CompanyCovis Pharma Sarl

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Urological Agents

    Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)

    Adrenergic alpha-1 Receptor Antagonists

    Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    alpha-Adrenergic Blocker [EPC]; Adrenergic alpha-Antagonists [MoA]